Hirai Kaori, Takano Yoji, Uchio Eiichi, Kadonosono Kazuaki
Department of Ophthalmology, International Goodwill Hospital, Fukuoka, Fukuoka, Japan.
Clin Ophthalmol. 2012;6:133-8. doi: 10.2147/OPTH.S28886. Epub 2012 Jan 16.
To evaluate the therapeutic effects of atelocollagen absorbable punctal plugs.
Seventy-four eyes in 37 patients with dry eye disease (DED) underwent punctal plug occlusion using atelocollagen plugs and were followed up for 24 weeks. Subjective symptoms were evaluated using the ocular surface disease index (OSDI) questionnaire. Ocular surface disease parameters, including the Schirmer test, phenol red thread test, tear break-up time (TBUT), and fluorescein and Rose Bengal staining, were recorded before and 1, 4, 8, 16, and 24 weeks after treatment.
In comparison with the pretreatment data, the subjective symptoms and ocular surface disease parameters showed significant improvement after atelocollagen punctal occlusion. The average time of relapse was 17.4 ± 5.1 weeks. No severe complications occurred, and none of the plugs had to be removed because of local discomfort or epiphora.
Atelocollagen absorbable punctal plugs effectively improved ocular surface disorders in DED. These plugs are a safe and effective alternative in the treatment of DED.
评估去端胶原蛋白可吸收泪点塞的治疗效果。
37例干眼症(DED)患者的74只眼睛使用去端胶原蛋白泪点塞进行泪点堵塞,并随访24周。使用眼表疾病指数(OSDI)问卷评估主观症状。记录治疗前以及治疗后1、4、8、16和24周的眼表疾病参数,包括泪液分泌试验、酚红棉线试验、泪膜破裂时间(TBUT)以及荧光素和孟加拉玫瑰红染色。
与治疗前数据相比,去端胶原蛋白泪点堵塞后主观症状和眼表疾病参数有显著改善。平均复发时间为17.4±5.1周。未发生严重并发症,且没有一个泪点塞因局部不适或溢泪而必须取出。
去端胶原蛋白可吸收泪点塞有效改善了干眼症患者的眼表疾病。这些泪点塞是治疗干眼症的一种安全有效的替代方法。